Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › JBCHEPHARM

JBCHEPHARM

JB Chemicals & Pharmaceuticals Limited
Mid-capPharma ↗

What the six lenses say about JBCHEPHARM — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹2506.0
2026-07-16
VWAP · 1Y anchor
₹2003
+25.1% from VWAP
P/E · TTM
55.5×
TTM EPS ₹45.2
52-week range
100%
position low→high
RSI(14)
84
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How JBCHEPHARM’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Mid-cap cohortDRaw
Technical——›

The actual numbers

Price vs VWAP (1y)+25.1%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+23.8%
Price vs 50-EMA+11.0%
RSI(14)84
RS vs Nifty 500 · 3M+24.2%
RS vs sector · 3M+11.1%
52-week range100%
Volume vs 30d avg9.44×
Volume vs 60d avg11.48×
ATR(14) · volatility65.1
Bollinger width · vol contraction0.171
FundamentalD660›

The actual numbers

Return on equity (ROE)18.9%
Return on capital (ROCE)25.4%
Operating margin23.1%
Net margin17.1%
Revenue growth · YoY+5.9%
EPS growth · YoY+6.4%
Debt / equity0.00×

Full 8-quarter history in the financials table below.

Valuation——›

The actual numbers

P/E (TTM)55.5×
TTM EPS₹45.2
52-week range100%
CatalystD124›

The actual numbers

Earnings & momentum22
Capital actions15
Governance53

Every filing in the corporate-announcements panel below.

Flow——›

The actual numbers

Promoter holding48.8%
Delivery · 30d avg61.3%
Up/down-day asymmetry-2.5pp

Evidence

no delivery data — flow is delivery-only

How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Mid-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( — + — ) ÷ 2 = —(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Below threshold
0
Conviction score 0/100 · avg-decile strength —/10
Conviction score0/100›
Technical›
FundamentalD6›
Valuation›
CatalystD1›
Flow›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-07-16.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+0.6pp
+2.1pp
+13.9pp
+27.4pp
+37.9pp
+55.9pp
Nifty 500
Broad-market baseline
+0.5pp
+1.3pp
+13.1pp
+24.2pp
+32.6pp
+52.3pp
Sector
Own-sector index
—
—
+6.6pp
+11.1pp
+14.6pp
+36.3pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

JBCHEPHARM daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
2506.00+18.40

Relative strength

RS vs baseline · rebased to 100

JBCHEPHARM ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
138.85+0.64

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)1,0041,0019639491,0941,0851,065904
↳ change QoQ—-0.4%-3.7%-1.5%+15.3%-0.8%-1.8%-15.1%
EBITDA (₹cr)286280263226301310296201
EBITDA margin28.5%28.0%27.3%23.8%27.5%28.6%27.8%22.2%
PAT (₹cr)177175162146202208198101
↳ change QoQ—-1.3%-6.9%-10.1%+38.4%+3.0%-4.8%-49.0%
Net margin17.6%17.4%16.9%15.4%18.5%19.2%18.6%11.2%
EPS (₹)11.3911.2410.469.3612.9713.2712.636.31
D/E————————
YoY growth · Mar '26Revenue -4.7% YoYPAT -30.8% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 13 Jul '26
    LOWgovernance
    Suspension of Trading
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 8 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 7 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 6 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 1 Jul '26
    MEDIUMgovernance
    Disclosure under SEBI Takeover Regulations
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 30 Jun '26
    LOWgovernance
    Retirement
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 15 Jun '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 13 Jun '26
    HIGHearnings
    Reply to Clarification- Financial results
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 12 Jun '26
    MEDIUMgovernance
    Resignation of Director/KMP/SMP
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 12 Jun '26
    MEDIUMgovernance
    Resignation
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 27 May '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 25 May '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 20 May '26
    HIGHearnings
    Clarification - Financial Results
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 13 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 12 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma